Akari Therapeutics plc has published its annual report and consolidated financial statements for the year ended 31 December 2024. The report provides an overview of the company's performance, highlighting its strategic engagement with key stakeholders including investors, employees, regulatory bodies, and suppliers. Akari continues to focus on maintaining strong relationships and compliance with regulatory frameworks from agencies such as the FDA and EMA. The company emphasizes its commitment to acting in good faith and promoting long-term success for its members. The full report can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.